HOUSTON--(BUSINESS WIRE)--Oct 23, 2023--<em>Kiromic BioPharma, Inc. (OTC PINK: KRBP) (鈥淜iromic鈥� or the 鈥淐ompany鈥�)</em>, a clinical-stage, fully-integrated biotherapeutics company using its proprietary DIAMOND 庐 artificial intelligence and data mining ...
BOSTON--(BUSINESS WIRE)--Oct 23, 2023--Bicara Therapeutics, a clinical-stage biotechnology company developing dual-action biologics to elicit a potent and durable immune response, today announced the presentation of updated, positive interim data from its ongoing, open-label Phase 1/1b dose ...
PALO ALTO, Calif.--(BUSINESS WIRE)--Oct 23, 2023--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that initial results from the PEGASUS trial suggest liquid biopsy may be used in post-surgical clinical management to reduce unnecessary toxicity from ...
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Oct 22, 2023--Updated results from the <a ...
ALAMEDA, Calif.--(BUSINESS WIRE)--Oct 22, 2023--<a ...
RAHWAY, N.J.--(BUSINESS WIRE)--Oct 21, 2023--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from the Phase 3 LITESPARK-005 trial investigating WELIREG, Merck鈥檚 first-in-class, oral hypoxia-inducible factor-2 alpha (HIF-2a) inhibitor, for the ...